frexalimab
Phase 3- Indications
- Multiple sclerosis, Systemic lupus erythematosus, Type 1 diabetes
Company intelligence / Profile preview
ImmuNext
Lebanon, New Hampshire, United Statesimmunext.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 3
01
Overview
ImmuNext is developing immunomodulatory therapeutics with multiple programs in various stages. Their lead product Frexalimab (CD40L inhibitor) is in Phase 3 for Multiple Sclerosis, while Onvatilimab (VISTA antagonist) is pending for solid tumors. The company has established significant partnerships with major pharmaceutical companies for their pipeline assets.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Monoclonal antibodiesImmunomodulatory therapeutics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Beyond the preview
Go deeper on ImmuNext.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmuNext.